The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

A newly discovered tectonic "regime" may explain why Earth has active plates while Venus remains stagnant. When you purchase through links on our site, we may earn an affiliate commission. Here’s how ...

Georgia’s Dunaway Gardens will be the new home for the Sundance Institute Episodic Lab program. Located in Newnan, Ga., Dunaway Gardens will be host to Sundance Institute’s immersive six-day program ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min National celebrity Bill Nye ...

Home-based high-intensity aerobic training was associated with greater improvement in cerebellar ataxia symptoms, fitness, and fatigue compared with guidelines-recommended balance training in a ...

In a nutshell: A few years after the episodic game formula brought Telltale to its knees, a new studio founded by former members of the Malibu-based company is once again experimenting with a weekly ...

Cerebellum (Latin: "little brain") in orange. Cerebellar means "relating to the cerebellum." Source: 3dMediSphere / Shutterstock Since the 1970s, I've been intrigued by the cerebellum's role in peak ...

Not only can such devices be awkward, many people also perceive them as being stigmatizing. That's where the GyroPack backpack comes in. The device was first developed by Prof. Heike Vallery's team at ...

An innovative backpack, incorporating aerospace technology, shows promise as a balance aid for patients with the movement disorder ataxia. Research conducted by Radboud university medical center, in ...

Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...